Free Trial

Aeterna Zentaris (AEZS) Competitors

Aeterna Zentaris logo
$3.41 0.00 (0.00%)
As of 07/3/2025

AEZS vs. TENX, CARA, FBLG, CVKD, CYTH, BCAB, OVID, ALXO, NNVC, and CALC

Should you be buying Aeterna Zentaris stock or one of its competitors? The main competitors of Aeterna Zentaris include Tenax Therapeutics (TENX), Cara Therapeutics (CARA), FibroBiologics (FBLG), Cadrenal Therapeutics (CVKD), Cyclo Therapeutics (CYTH), BioAtla (BCAB), Ovid Therapeutics (OVID), ALX Oncology (ALXO), NanoViricides (NNVC), and CalciMedica (CALC). These companies are all part of the "pharmaceutical products" industry.

Aeterna Zentaris vs. Its Competitors

Tenax Therapeutics (NASDAQ:TENX) and Aeterna Zentaris (NASDAQ:AEZS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

Tenax Therapeutics has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500. Comparatively, Aeterna Zentaris has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500.

Tenax Therapeutics has a net margin of 0.00% compared to Aeterna Zentaris' net margin of -760.32%. Tenax Therapeutics' return on equity of -31.51% beat Aeterna Zentaris' return on equity.

Company Net Margins Return on Equity Return on Assets
Tenax TherapeuticsN/A -31.51% -30.35%
Aeterna Zentaris -760.32%-83.45%-45.76%

In the previous week, Tenax Therapeutics' average media sentiment score of 0.00 equaled Aeterna Zentaris'average media sentiment score.

Company Overall Sentiment
Tenax Therapeutics Neutral
Aeterna Zentaris Neutral

Aeterna Zentaris has higher revenue and earnings than Tenax Therapeutics. Tenax Therapeutics is trading at a lower price-to-earnings ratio than Aeterna Zentaris, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tenax TherapeuticsN/AN/A-$17.60M-$2.48-2.40
Aeterna Zentaris$2.37M2.58-$16.55M-$14.86-0.23

1.7% of Tenax Therapeutics shares are owned by institutional investors. Comparatively, 0.7% of Aeterna Zentaris shares are owned by institutional investors. 3.7% of Tenax Therapeutics shares are owned by insiders. Comparatively, 0.1% of Aeterna Zentaris shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Tenax Therapeutics currently has a consensus target price of $17.50, indicating a potential upside of 193.62%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Tenax Therapeutics is more favorable than Aeterna Zentaris.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tenax Therapeutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.25
Aeterna Zentaris
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Tenax Therapeutics beats Aeterna Zentaris on 11 of the 14 factors compared between the two stocks.

Get Aeterna Zentaris News Delivered to You Automatically

Sign up to receive the latest news and ratings for AEZS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AEZS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AEZS vs. The Competition

MetricAeterna ZentarisPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$6.11M$812.96M$5.56B$9.05B
Dividend YieldN/A4.84%5.24%3.99%
P/E Ratio-0.231.1519.9620.26
Price / Sales2.58230.41419.56119.26
Price / CashN/A23.4426.2128.59
Price / Book0.236.328.035.65
Net Income-$16.55M-$27.99M$3.18B$249.15M
7 Day Performance2.10%2.10%2.93%3.28%
1 Month Performance-8.33%9.39%1.72%3.95%
1 Year Performance-28.21%11.51%34.39%20.98%

Aeterna Zentaris Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AEZS
Aeterna Zentaris
N/A$3.41
flat
N/A-28.2%$6.11M$2.37M-0.2320
TENX
Tenax Therapeutics
1.265 of 5 stars
$5.87
+0.3%
$17.50
+198.4%
+89.8%$24.34MN/A-2.369
CARA
Cara Therapeutics
0.3356 of 5 stars
N/AN/AN/A$24.33M$7.14M-0.2580News Coverage
Gap Down
High Trading Volume
FBLG
FibroBiologics
2.2861 of 5 stars
$0.63
+1.1%
$13.00
+1,966.8%
-87.0%$24.22MN/A-3.0110Gap Up
CVKD
Cadrenal Therapeutics
2.8547 of 5 stars
$12.05
+0.0%
$32.00
+165.5%
N/A$23.75MN/A-1.304Positive News
Gap Up
CYTH
Cyclo Therapeutics
N/A$0.72
flat
$0.95
+31.8%
N/A$23.72M$870.73K-0.809
BCAB
BioAtla
2.7324 of 5 stars
$0.40
+1.0%
$5.00
+1,150.0%
-71.2%$23.60M$11M-0.3360News Coverage
Gap Down
OVID
Ovid Therapeutics
4.2249 of 5 stars
$0.33
-0.6%
$3.13
+852.7%
-53.9%$23.32M$570K-0.9460
ALXO
ALX Oncology
2.6469 of 5 stars
$0.43
+3.6%
$3.30
+667.4%
-91.4%$22.96MN/A-0.1740Positive News
Gap Up
NNVC
NanoViricides
1.0876 of 5 stars
$1.40
flat
N/A-20.0%$22.50MN/A-1.9420Gap Down
CALC
CalciMedica
3.0734 of 5 stars
$1.71
+6.8%
$18.00
+953.2%
-61.8%$22.17MN/A-1.0230

Related Companies and Tools


This page (NASDAQ:AEZS) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners